


30

1647



Practitioner's Docket No. 1059.00051

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Dexian Dou, et al.

Serial Number: 09/914,277

Group Art Unit: 1647

Filed: March 25, 2002

For: ANTI-ANGIOGENIC KRINGLE PROTEIN AND ITS MUTANT

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR 1.97(e)(1)**

Mail Stop DD  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Provided herewith are copies of patents and publications as listed in the attached PTO-1449 (supplemental).

Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application mailed not more than three months prior to the filing of the statement. 37 CFR 1.97(e)(1).

While the statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. The filing of this statement does not mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

Please charge our Deposit Account No. 11-1449 for any additional fees or credit our account for any overpayment. **A duplicate of this transmittal is attached.**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington

D.C. 20231, on

(Date of Deposit)

8/26/03  
  
Angel Webb  
Signature

8/26/03  
Date of Signature

Respectfully submitted,

KOHN &amp; ASSOCIATES, PLLC

Kenneth I. Kohn  
Registration No. 30,955  
30500 Northwestern Hwy.  
Suite 410  
Farmington Hills, MI 48334  
(248) 539-5050


Date: August 26, 2003



# MANUAL OF PATENT EXAMINING PROCEDURE

Sheet 1 of 3

Form PTO-1449				Docket Number (Optional) 1059.00051		Application Number 09/914,277	
<b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>				Applicant Dexian Dou, et al.			
				Filing Date 03/25/02		Group Art Unit 1647	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date Pertinent Pages, Etc.)</i>							
		Bennett WF, Paoni NF, Keyt BA, Botstein D, Jones AJ, Presta L, Wurm FM, Zoller MJ. HIGH RESOLUTION ANALYSIS OF FUNCTIONAL DETERMINANTS ON HUMAN TISSUE-TYPE PLASMINOGEN ACTIVATOR, Journal of Biological Chemistry 1991, 266(8):5191-5201.					
		Cao Y, Ji RW, Davidson D, Schaller J, Marti D, Sohndel S, McCance SG, O'Reilly MS, Llinas M, Folkman J. KRINGLE DOMAINS OF HUMAN ANGIOSTATIN. CHARACTERIZATION OF THE ANTI-PROLIFERATION ACTIVITY ON ENDOTHELIAL CELLS, Journal of Biological Chemistry 1996; 271:297431-29467.					
		Cao Y., Chen A, An SSA, Ji RW, Davidson D, Llinas M. KRINGLE 5 OF PLASMINOGEN IS A NOVEL INHIBITOR OF ENDOTHELIAL CELL GROWTH, Journal of Biological Chemistry 1997, 272:22924-22928.					
		Chang et al. SOMATIC GENE THERAPY, CRC Press, Ann Arbor, MI 1995.					
		Cheng XF, Brohlin M, Pohl G, Back O, Wallen P. BINDING OF TISSUE PLASMINOGEN ACTIVATOR TO ENDOTHELIAL CELLS, Thrombosis Research 1955, 77(2)149-164.					
		Dong Z, Kumar R, Yang X, Fidler IJ. MACROPHAGE-DERIVED METALLOELASTASE IS RESPONSIBLE FOR THE GENERATION OF ANGIOSTATIN IN LEWIS LUNG CARCINOMA, C II 1997, 88:801-810.					
		Dunn T. OXYGEN AND CANCER, NorthCarolina Medical Journal 1997,58:140-143.					
		Fisher B, Gunduz N, Saffer EA. INFLUENCE OF THE INTERVAL BETWEEN PRIMARY TUMOR REMOVAL AND CHEMOTHERAPY ON KINETICS AND GROWTH OF METASTASES, Cancer Research, 43:1488-1492.					
		Folkman J, D'Amore PA, BLOOD VESSEL FORMATION: WHAT IS ITS MOLECULAR BASIS?, Cell 1996, 87(7):1153-1155.					
		Forsgren M, Râden B, Israelsson M, Larsson K, HedËn LO. MOLECULAR CLONING AND CHARACTERIZATION OF A FULL-LENGTH cDNA CLONE FOR HUMAN PLASMINOGEN. FEBS Letters 1987, 213(2):254-260.					
		Garcia G, Mar P, Mullin D, Walker J, Prather N. THE <i>E coli</i> dna Y GENE ENDOCES AN ARGININE TRANSFER RNA, Cell 1986, 45:453-459.					
		Goldhaber SI, Kessler CM, Heit J, Markis J, Sharma GV, Dawley D, Nagel JS, Meyerovitz M, Kim D, Vaughn DE. RANDOMIZED CONTROLLED TRIAL OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR VERSUS UROKINASE IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM, Lancet 1988, 2(8606):293-298.					
		Horrevoets A, Smilde A, de Vries C, Pannekoek H. THE SPECIFIC ROLES OF FINGER AND KRINGLE 2 DOMAINS OF TISSUE-TYPE PLASMINOGEN ACTIVATOR DURING IN VITRO FIBRINOLYSIS, Journal of Biological Chemistry 1994, 269(17):12639-12644.					



		Bruska KA, Rolnick F, Huskey M, Alvarez U, Cheresch D. ENGAGEMENT OF THE OSTEOCLAST INTEGRIN ALPHA V BETA 3 BY OSTEOPONTIN STIMULATES PHOSPHATIDYLINOSITOL 3-HYDROXYL KINASE ACTIVITY, <i>Endocrinology</i> 1995, 136(7):2984-2992.
		Hu GF. LIMITED PROTEOLYSIS OF ANGIOSTATIN BY ELASTASE IS REGULATED BY PLASMINOGEN, <i>J Protein Chem</i> 1997, 16:669-679.
		Jendrasschak E., Sage EH. REGULATION OF ANGIOGENESIS BY SPARC AND ANGIOSTATIN: IMPLICATIONS FOR TUMOR CELL BIOLOGY, <i>Seminars in Cancer Biology</i> 1996, 7:139-146.
		Ji WR, Barrientos LG, Llinas M, Gray H, Villarreal X, DeFord ME, Castellino FJ, Kramer RA, Trail PA. SELECTIVE INHIBITION BY KRINGLE 5 OF HUMAN PLASMINOGEN ON ENDOTHELIAL CELL MIGRATION, AN IMPORTANT PROCESS IN ANGIOGENESIS, <i>Biochemical and Biophysical Research Communications</i> 1998, 247:414-419.
		Liotta LA, Steeg PS, Stetler-Stevenson WG. CANCER METASTASIS AND ANGIOGENESIS; AN IMBALANCE OF POSITIVE AND NEGATIVE REGULATION, <i>Cell</i> 1991, 64:327-336.
		The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group, A SYSTEM APPROACH TO IMMEDIATE EVALUATION AND MANAGEMENT OF HYPERACUTE STROKE. EXPERIENCE AT EIGHT CENTERS AND IMPLICATIONS FOR COMMUNITY PRACTICE AND PATIENT CARE, <i>Stroke</i> 1997, 28(8):1530-1540.
		Nesheim M, Fredenburgh JC, Larsen GR. THE DISSOCIATION CONSTANTS AND STOICHIOMETRIES OF THE INTERACTIONS OF LYS-PLASMINOGEN AND CHLOROMETHYL KETONE DERIVATIVES OF TISSUE PLASMINOGEN ACTIVATOR AND THE VARIANT DELTA FE IX WITH INTACT FIBRIN, <i>Journal of Biological Chemistry</i> 1990, 265(35) 21541-21548.
		O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead J, Olsen B, Folkman J. ENDOSTATIN: AN ENDOGENOUS INHIBITOR OF ANGIOGENESIS AND TUMOR GROWTH, <i>Cell</i> 1997, 88:277-285.
		O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, Lane W, Cao Y, Sage EH, Folkman J. ANGIOSTATIN: A NOVEL ANGIOGENESIS INHIBITOR THAT MEDIATES THE SUPPRESSION OF METASTASES BY A LEWIS LUNG CARCINOMA, <i>Cell</i> 1994, 79:315-328.
		O'Reilly M, Rosenthal R, Sage EH, Smith S, Holmgren L, Moses M, Shing Y, Folkman J. THE SUPPRESSION OF TUMOR METASTASES BY A PRIMARY TUMOR, <i>Surg Forum</i> 1993, 44:474-476.
		O'Reilly MS, Holmgren L, Chen C, Folkman J. ANGIOSTATIN INDUCES AND SUSTAINS DORMANCY OF HUMAN PRIMARY TUMORS IN MICE, <i>Nature Med</i> 1996, 2:689-692.
		Parker JA, Markis JE, Palla A, Goldhaber SZ, Royal HD, Tumei S, Kim D, Rustgi AK, Holman BL, Kolodny GM. PULMONARY PERFUSION AFTER rt-PA THERAPY FOR ACUTE EMBOLISM: EARLY IMPROVEMENT ASSESSED WITH SEGMENTAL PERFUSION SCANNING, <i>Radiology</i> 1988, 166(2):441-445.
		Patterson BC, Sang QA. ANGIOSTATIN-CONVERTING ENZYME ACTIVITIES OF HUMAN MATRILYSIN (MMP-7) AND GELATINASE B/TYPE IV COLLAGENASE (MMP-9), <i>J Biol Chem</i> 1997, 272:28823-28825.
		Pathy L. EVOLUTION OF THE PROTEASES OF BLOOD COAGULATION AND FIBRINOLYSIS BY ASSEMBLY FROM MODULES, <i>Cell</i> 1985, 41(3):657-663.
		Saarela J, Ylikarppa R, Rehn M, Purmonen S, Pihlajaniemi T. COMPLETE PRIMARY STRUCTURE OF TWO VARIANT FORMS OF HUMAN TYPE XVIII COLLAGEN AND TISSUE-SPECIFIC DIFFERENCES IN THE EXPRESSION OF THE CORRESPONDING TRANSCRIPTS, <i>Matrix Biology</i> 1997, 16:319-328.
		Standker L, Schrader M, Kanse SM, Jurgens M, Forssmann WG, Preissner KT. ISOLATION AND CHARACTERIZATION OF THE CIRCULATING FORM OF HUMAN ENDOSTATIN. <i>FEBS Letters</i> 1997, 420(2-3):129-133.
		Stathakis P, Fitzgerald M, Mathrhais LJ, Chesterman CN, Hogg PJ. GENERATION OF ANGIOSTATIN BY REDUCTION AND PROTEOLYSIS OF PLASMIN. CATALYSIS BY A PLASMIN REDUCTASE SECRETED BY CULTURED CELLS, <i>J. Biol Chem</i> 1997, 272:20647-20645.
		Stump DC, Califf RM, Topol EJ, Sigmon K, Thorton D, Masek R, Anderson L, Collen D. PHARMACODYNAMICS OF THROMBOLYSIS WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR. CORRELATIONS WITH CHARACTERISTICS OF AND CLINICAL OUTCOMES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION, The TAMI Study Group, <i>Circulation</i> 1989, 80(5):1222-1230.
		Thimier R, Spangenberg HC, Blum HE. ANGIOSTATIN. A BIOLOGICAL INHIBITOR OF TUMOR ANGIOGENESIS, <i>Deutsche Medizinische Wochenschrift</i> 1997, 122:413-414.
		Wardlaw JM, Warlow CP, Consell C. SYSTEMATIC REVIEW OF EVIDENCE ON THROMBOLYTIC THERAPY FOR ACUTE ISCHAEMIC STROKE, <i>Lancet</i> 1997, 350(9078):607-614.

	White FC, Carroll SM, Kamps MP. VEGF mRNA IS REVERSIBLY STABILIZED BY HYPOXIA AND PERSISTENTLY STABILIZED IN VEGF-OVEREXPRESSING HUMAN TUMOR CELL LINE, Growth Factors 1995, 12(4):289-301.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.	

PTO/SB/ 08 (2-92)  
DEPARTMENT OF COMMERCE

Patent and Trademark Office; U.S.

